A Novel soluble form of Tim-3 associated with severe graft-versus-host disease

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 9, 2013, Pages 1323-1330

  Hansen, John A ^a,b   Hanash, Samir M ^a,c   Tabellini, Laura ^a   Baik, Chris ^a   Lawler, Richard L ^a   Grogan, Bryan M ^a   Storer, Barry ^a   Chin, Alice ^a   Johnson, Melissa ^a   Wong, Chee Hong ^a   Zhang, Qing ^a   Martin, Paul J ^a,b   McDonald, George B ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Graft versus host disease; Hematopoietic cell; Marrow transplantation; Proteomics; TIM 3; Transplantation

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BUSULFAN; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; DAPSONE; GANCICLOVIR; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; SULFAMETHOXAZOLE; TRIMETHOPRIM; URSODEOXYCHOLIC ACID; HAVCR2 PROTEIN, HUMAN; MEMBRANE PROTEIN;

ACUTE LEUKEMIA; ADAPTIVE IMMUNITY; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD SAMPLING; CD8+ T LYMPHOCYTE; CHOLESTASIS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; T LYMPHOCYTE; VALIDATION STUDY; WHOLE BODY RADIATION; ADOLESCENT; BLOOD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MASS SPECTROMETRY; MEMBRANE PROTEINS; MIDDLE AGED; PROTEOMICS; YOUNG ADULT;

EID: 84882797493     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.06.011     Document Type: Article

References (52)

1. Kuchroo V.K., Dardalhon V., Xiao S., Anderson A.C. New roles for TIM family members in immune regulation. Nat Rev Immunol 2008, 8:577-580.
2. Sehrawat S., Reddy P.B., Rajasagi N., et al. Galectin-9/TIM-3 interaction regulates virus-specific primary and memory CD8 T cell response. PLoS Pathog 2010, 6:e1000882.
3. Sehrawat S., Suryawanshi A., Hirashima M., Rouse B.T. Role of Tim-3/galectin-9 inhibitory interaction in viral-induced immunopathology: Shifting the balance toward regulators. JImmunol 2009, 182:3191-3201.
4. Zhu C., Anderson A.C., Schubart A., et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005, 6:1245-1252.
5. Hastings W.D., Anderson D.E., Kassam N., et al. TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. Eur J Immunol 2009, 39:2492-2501.
6. Chiba S., Baghdadi M., Akiba H., et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 2012, 13:832-842.
7. Katayama H., Paczesny S., Prentice R., et al. Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. Genome Med 2009, 1:47.
8. Oikawa T., Kamimura Y., Akiba H., et al. Preferential involvement of Tim-3 in the regulation of hepatic CD8+ T cells in murine acute graft-versus-host disease. JImmunol 2006, 177:4281-4287.
9. Hafler D.A., Kuchroo V. TIMs: Central regulators of immune responses. JExp Med 2008, 205:2699-2701.
10. Ngiow S.F., Teng M.W., Smyth M.J. Prospects for TIM3-targeted antitumor immunotherapy. Cancer Res 2011, 71:6567-6571.
11. Veenstra R.G., Taylor P.A., Panoskaltsis-Mortari A., et al. Contrasting acute graft-versus-host-disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells. Blood 2012, 120:682-690.
12. Kashio Y., Nakamura K., Abedin M.J., et al. Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. JImmunol 2003, 170:3631-3636.
13. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. NEngl J Med 2010, 363:2091-2101.
14. Mielcarek M., Storer B.E., Boeckh M., et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 2009, 113:2888-2894.
15. Hockenbery D.M., Cruickshank S., Rodell T.C., et al. Arandomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 2007, 109:4557-4563.
16. Hsu K.C., Gooley T., Malkki M., et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2006, 12:828-836.
17. Kreisel W., Dahlberg M., Bertz H., et al. Endoscopic diagnosis of acute intestinal GVHD following allogeneic hematopoietic SCT: A retrospective analysis in 175 patients. Bone Marrow Transplant 2012, 47:430-438.
18. Cahn J.Y., Klein J.P., Lee S.J., et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: A joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 2005, 106:1495-1500.
19. Leisenring W.M., Martin P.J., Petersdorf E.W., et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood 2006, 108:749-755.
20. Foley R., Couban S., Walker I., et al. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogenic bone marrow transplantation. Bone Marrow Transplant 1998, 21:769-773.
21. Nakamura H., Komatsu K., Ayaki M., et al. Serum levels of soluble IL-2 receptor, IL-12, IL-18, and IFN-gamma in patients with acute graft-versus-host disease after allogeneic bone marrow transplantation. JAllergy Clin Immunol 2000, 106:S45-S50.
22. Shaiegan M., Iravani M., Babaee G.R., Ghavamzadeh A. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients. Transpl Immunol 2006, 15:223-227.
23. Paczesny S., Krijanovski O.I., Braun T.M., et al. Abiomarker panel for acute graft-versus-host disease. Blood 2009, 113:273-278.
24. Holler E., Kolb H.J., Möller A., et al. Increased serum levels of tumor necrosis factor a precede major complications of bone marrow transplantation. Blood 1990, 75:1011-1016.
25. Miyamoto T., Akashi K., Hayashi S., et al. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transplant 1996, 17:185-190.
26. Or R., Kalinkovich A., Nagler A., et al. Soluble tumor necrosis factor (sTNF) receptors: A possible prognostic marker for bone marrow transplantation-related complications. Cytokines Mol Ther 1996, 2:243-250.
27. Grimm J., Zeller W., Zander A.R. Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantations as a marker for GVHD. Bone Marrow Transplant 1998, 21:29-32.
28. Paczesny S., Braun T.M., Levine J.E., et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med 2010, 2:13ra2.
29. Ferrara J.L., Harris A.C., Greenson J.K., et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 2011, 118:6702-6708.
30. Vander Lugt M.T., Braun T., Ferrara J.L.M., et al. Plasma concentration of suppressor of tumorigenicity 2 (ST2), the IL33 receptor, at initiation of graft versus host disease therapy predicts day 28 response and day 180 survival post-treatment. Biol Blood Marrow Transplant 2012, 18:S201-S202. [abstr.].
31. Ayabe T., Satchell D.P., Wilson C.L., et al. Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat Immunol 2000, 1:113-118.
32. Yilmaz O.H., Katajisto P., Lamming D.W., et al. mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature 2012, 486:490-495.
33. Luft T., Dietrich S., Falk C., et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood 2011, 118:1685-1692.
34. Harris A.C., Ferrara J.L., Braun T.M., et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood 2012, 119:2960-2963.
35. Ruutu T., Eriksson B., Remes K., et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002, 100:1977-1983.
36. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
37. Ponec R.J., Hackman R.C., McDonald G.B. Endoscopic and histologic diagnosis of intestinal graft-versus-host disease after marrow transplantation. Gastrointest Endosc 1999, 49:612-621.
38. Faca V., Coram M., Phanstiel D., et al. Quantitative analysis of acrylamide labeled serum proteins by LC-MS/MS. JProteome Res 2006, 5:2009-2018.
39. Faca V., Pitteri S.J., Newcomb L., et al. Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. JProteome Res 2007, 6:3558-3565.
40. Smyth G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3. Article3.
41. Meyers J.H., Sabatos C.A., Chakravarti S., Kuchroo V.K. The TIM gene family regulates autoimmune and allergic diseases. Trends Mol Med 2005, 11:362-369. (Review).
42. Anderson A.C., Anderson D.E., Bregoli L., et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 2007, 318:1141-1143.
43. Geng H., Zhang G.M., Li D., et al. Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell-mediated immune response. JImmunol 2006, 176:1411-1420.
44. Khademi M., Illes Z., Gielen A.W., et al. TCell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. JImmunol 2004, 172:7169-7176.
45. Frisancho-Kiss S., Nyland J.F., Davis S.E., et al. Cutting edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity. JImmunol 2006, 176:6411-6415.
46. Monney L., Sabatos C.A., Gaglia J.L., et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002, 415:536-541.
47. Nakae S., Iikura M., Suto H., et al. TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cells. Blood 2007, 110:2565-2568.
48. Sanchez-Fueyo A., Tian J., Picarella D., et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol 2003, 4:1093-1101.
49. Sabatos C.A., Chakravarti S., Cha E., et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol 2003, 4:1102-1110.
50. Koguchi K., Anderson D.E., Yang L., et al. Dysregulated T cell expression of TIM3 in multiple sclerosis. JExp Med 2006, 203:1413-1418.
51. Yang L., Anderson D.E., Kuchroo J., Hafler D.A. Lack of TIM-3 immunoregulation in multiple sclerosis. JImmunol 2008, 180:4409-4414.
52. Ndhlovu L.C., Lopez-Verges S., Barbour J.D., et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 2012, 119:3734-3743.